West Paces Advisors’s Quest Diagnostics DGX Stock Holding History

West Paces Advisors’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.6K	Buy	+69	New	+$13.5K	﹤0.01%	365
2025 Q2	–	Sell	-72	Closed	-$12.2K	–	302
2025 Q1	$12.2K	Hold	72	–	–	﹤0.01%	330
2024 Q4	$10.9K	Hold	72	–	–	﹤0.01%	342
2024 Q3	$11.2K	Hold	72	–	–	﹤0.01%	342
2024 Q2	$9.86K	Hold	72	–	–	﹤0.01%	353
2024 Q1	$9.58K	Sell	72 -2	-3%	-$259	﹤0.01%	364
2023 Q4	$10.2K	Buy	74 +16	+28%	+$2.1K	﹤0.01%	359
2023 Q3	$7.07K	Hold	58	–	–	﹤0.01%	371
2023 Q2	$8.15K	Hold	58	–	–	﹤0.01%	386
2023 Q1	$8.21K	Hold	58	–	–	﹤0.01%	384
2022 Q4	$9.07K	Hold	58	–	–	﹤0.01%	360
2022 Q3	$7.12K	Hold	58	–	–	﹤0.01%	368
2022 Q2	$7.71K	Hold	58	–	–	﹤0.01%	385
2022 Q1	$7.94K	Hold	58	–	–	﹤0.01%	382
2021 Q4	$10K	Hold	58	–	–	﹤0.01%	374
2021 Q3	$8.43K	Hold	58	–	–	﹤0.01%	372
2021 Q2	$7.65K	Hold	58	–	–	﹤0.01%	383
2021 Q1	$7.44K	Buy	+58	New	+$7.15K	﹤0.01%	358
2017 Q3	–	Sell	-2	Closed	-$222	–	480
2017 Q2	$222	Hold	2	–	–	﹤0.01%	497
2017 Q1	$196	Hold	2	–	–	﹤0.01%	497
2016 Q4	$184	Buy	+2	New	+$172	﹤0.01%	549

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

West Paces Advisors's DGX Position: Q2 2026 in Review

West Paces Advisors opened a new position in Quest Diagnostics (DGX) in Q2 2026: 69 shares worth $14.6K. The stake represents ﹤0.01% of the portfolio and ranks #365 among its holdings. This is a return to the name: West Paces Advisors previously reported a position in DGX as recently as Q1 2025.

West Paces Advisors first reported a position in DGX in Q4 2016 and has held it in 21 quarters since. 1,107 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

West Paces Advisors held 69 shares of Quest Diagnostics worth $14.6K as of Q2 2026.
Quest Diagnostics was a new West Paces Advisors position in Q2 2026.
Quest Diagnostics made up ﹤0.01% of West Paces Advisors's portfolio in Q2 2026, its #365 holding.
West Paces Advisors first reported a position in Quest Diagnostics in Q4 2016 and has held it in 21 quarters since.
1,107 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on West Paces Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.